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Abstract 
Recent trends for the determination of pharmaceutical drugs in wastewaters focus on the 
development of rapid multi-residue methods.  These encompass a large number of drugs (up 
to 90) of varying physicochemical composition (hydrophobicity, molecular weight etc) at ng 
l
-1
 concentrations in the aqueous phase of complex heterogeneous matrices.  These are well 
suited for drug determination in secondary effluents which contain detectable concentrations 
of pharmaceuticals.  Drugs are not routinely monitored for in particulate phases of 
wastewaters despite being essential for fate determination, particularly in secondary processes 
receiving relatively high concentrations of suspended solids.  Secondary effluents tend to 
contain multiple drugs, often above their proposed legislative targets for consent.  Thus, 
tertiary processing may be considered to enhance drug removal and provide additional 
environmental protection.  However, current analytical methods do not enable the efficacy of 
tertiary processes to be fully ascertained due to the inherently lower drug concentrations 
achieved.  Existing method optimisation is required to lower detection capabilities for tertiary 
process monitoring.  This would aid the understanding of breakdown reaction completeness 
and the criticality between parent drug and degradation product concentrations.  Numerous 
degradation products are formed by biological and chemical processes which can exhibit 
toxicity.  The complimentary use of biological assays here would improve understanding of 
the synergistic toxicological effect of multiple drugs and their degradation products at low 
concentration.  Additionally, tertiary processes receive secondary effluents comprising 
comparatively high concentrations of dissolved organics (e.g., colloids).  However, 
knowledge of drug behaviour in the charged colloidal fraction of wastewater and its impact to 
treatment is limited.  Monitoring and understanding here is needed to develop tertiary process 
diagnosis and optimisation. 
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1. Introduction  
It is well established that wastewater contains a diverse range of anthropogenic compounds 
[1] and that their quantitative analysis poses numerous problems analytically, both in terms of 
extraction efficiency [2] and interference from co-extractives [3].  Through medical use large 
numbers of drugs are now included in this group of determinants [4-7].  A clear trend in 
legislation has been a lowering of acceptable environmental concentrations (e.g., 17α-
ethinylestradiol (EE2)) and analytical method development has become an iterative process to 
achieve ever lower detection limits [8-9] as further potential environmental health issues 
emerge [10]. A growing understanding of the possible environmental impact to aquatic 
ecosystems has led to the classification of diclofenac and the steroid estrogen EE2 as priority 
hazardous chemicals [11-12].  These drugs have proposed environmental quality standards 
(EQS) of 100 ng l
-1
 and 0.035 ng l
-1
 respectively, and require monitoring to ensure compliance 
to ‘good’ water status [11-12].  The effects of EE2, which results in intersex in male fish, are 
the most studied of the drugs in the environment [13].  Concentrations of EE2 below 1 ng l
-1
 
are known to cause intersex and vitellogenin induction in male fish during laboratory studies.  
The environmental impact of other drugs and mixtures is less clear.  However, it has been 
demonstrated that a mixture of acetaminophen, carbamazepine, gemfibrozil and venlaflaxine 
(in the low µg l
-1
 range) had a significant impact to fish embryo development in the short term 
[14].  The chronic impact of drugs (i.e., ecological and evolutionary), either individually or as 
mixtures, remains unknown [15].  Without such information it is desirable to limit entry of 
these chemicals into the aquatic environment.  A total of 12 drugs of varying therapeutic class 
(ibuprofen, diclofenac, naproxen, ketoprofen, carbamazepine, bezafibrate, propranolol, 
fluoxetine, EE2, ofloxacin, erythromycin and oxytetracycline) are highlighted in this review 
to represent a variety of physicochemical compositions (e.g., molecular size, hydrophobicity) 
(Table 1).  This includes those most studied in the literature [7, 17-18] and those in national 
studies (i.e., the UK Chemical Investigations Programme (CIP)) [19].  The CIP found 
diclofenac, propranolol, fluoxetine, EE2, erythromycin and oxytetracycline above their 
indicative legislative targets for consent (10 ng l
-1
 for those not listed as priority hazardous 
substances) in over 50 % of effluents studied [19].  Consequently, a variety of drugs have 
been observed in surface waters in the ng l
-1
 range (Table 2).  This underpins the need to 
understand drug fate during wastewater treatment for process/strategy optimisation.   
 
Determining drug fate during wastewater treatment relies on the application of robust 
analytical methodologies.  These require the ability to simultaneously determine a number of 
drugs, of differing physicochemical properties, within environmental matrices comprised of 
comparatively high concentrations of complex bulk organics [23].  The high complexity of 
environmental matrices underlines the analytical challenge posed.  Drugs and their 
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Table 1. Physicochemical properties of pharmaceutical drugs present in crude wastewaters and 
secondary effluents [16] 
Drug 
MW 
/ g mol
-1
 
Water solubility  
/ mg l
-1
 
Henry’s law  
/ atm m
3
 mol
-1
 
VP  
/ mm Hg 
pKa Log Kow Log Koc 
Ibuprofen 206.30 21.0 1.52.10
-7
 1.86.10
-4
 4.91 3.79-3.97 2.35 
Diclofenac 296.15 2.4 4.73.10
-12
 2.18.10
-6
 4.15 4.02-4.51 2.61 
Naproxen 230.26 15.9 3.39.10
-10
 1.27.10
-6
 4.15 3.10-3.18 1.97 
Ketoprofen 254.28 51.0 2.12.10
-11
 6.81.10
-6
 4.45 3.00-3.12 2.08 
Carbamazepine 236.27 112 1.08.10
-10
 8.80.10
-8
 - 2.25-2.45 2.23 
Bezafibrate 361.82 7.9 2.12.10
-15
 6.12.10
-11
 - 4.25 2.31 
Propranolol 259.35 61.7 7.98.10
-13
 9.44.10
-8
 9.42 2.60-3.48 2.45 
Fluoxetine 309.33 60.3 8.90.10
-8
 2.52.10
-5
 - 4.05-4.65 4.97 
EE2 296.40 11.3 7.94.10
-12
 1.95.10
-9
 - 3.67-4.12 4.65 
Ofloxacin 361.37 2.8.10
4
 4.98.10
-20
 9.84.10
-13
 - <0 1.09 
Erythromycin 733.94 0.5 5.42.10
-29
 2.12.10
-25
 8.88 2.48-3.06 2.75 
Oxytetracycline 460.43 313 1.70.10
-25
 9.05.10
-23
 3.27 <0 1.87 
KEY: MW, molecular weight; VP, vapour pressure; pKa, acid dissociation constant; Log Kow, octanol-
water coefficient; Log Koc, organic carbon-water coefficient 
 
 
metabolites were first reported in wastewater effluents in the 1970’s [24].  Hignite et al [24] 
measured chlorophenoxyisobutyrate and salicylic acid in wastewater effluents at relatively 
high mean concentrations of 7 µg l
-1
 and 29 µg l
-1
, respectively.  Ion exchange 
chromatography was used for extraction followed by gas chromatography-mass spectrometry 
(GC-MS).  Numerous other drugs have been given significant attention recently due to the 
development of sophisticated analytical methodologies [17-18, 25].  Extraction media 
enabling simultaneous retention of acidic, basic and neutral species of varying polarities has 
aided this.  Furthermore, the coupling of liquid chromatography (LC), and particularly ultra-
performance liquid chromatography (UPLC) to MS has seen significant reductions in sample 
pre-treatment requirements and instrument analysis time [23].  Other than analytical 
difficulties, the variety of physicochemical behaviour (e.g., hydrophobicity) exhibited by 
drugs results in significant differences in their fate and removal during wastewater treatment 
[6, 26].  Tertiary treatment processes are being considered to enhance hazardous chemical 
removal to levels which comply with proposed EQS’s [27], as are the analytical methods 
capable of supporting their diagnosis and optimisation for this critical group of emerging 
chemicals.  This review addresses recent analytical trends for drug determination in 
environmental matrices used to facilitate fate studies.  Analytical requirements for further fate 
evaluation and tertiary process selection/optimisation are also discussed. 
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Table 2.  Recently reported occurrence of pharmaceutical drugs in surface waters  
Drug of 
interest 
Class Chemical structure 
Proposed 
legislative 
target / ng l
-1
 
Surface 
water
a
 / ng l
-1
 
Location 
Ibuprofen NSAID 
 
10
b
 
<0.3-56 
<6.4-542 
21-2,796 
UK 
Mainland Europe 
North America 
Diclofenac NSAID 
 
100
c
 
<0.5-261 
<12-154 
17-42 
UK 
Mainland Europe 
North America 
Naproxen NSAID 
 
- 
<0.3-55 
<3.1-109 
22 
UK 
Mainland Europe 
North America 
Ketoprofen NSAID 
 
- 
<0.5-4 
<15-517 
- 
UK 
Mainland Europe 
North America 
Carbamazepine Anti-epileptic 
 
- 
0.5-495 
<1.5-54 
1-1,238 
UK 
Mainland Europe 
North America 
Bezafibrate 
Lipid 
regulator 
 
- 
<10-66 
<2.0-26 
- 
UK 
Mainland Europe 
North America 
Propranolol Beta blocker 
 
10
b
 
<0.5-27 
<0.4-39 
53 
UK 
Mainland Europe 
North America 
Fluoxetine 
Anti-
depressant 
 
10
b
 
- 
<7.4-24 
<1.3-65 
UK 
Mainland Europe 
North America 
EE2 Contraceptive 
 
0.035
c
 
- 
- 
- 
UK 
Mainland Europe 
North America 
Ofloxacin Antibiotic 
 
10
b
 
- 
4.8-105 
- 
UK 
Mainland Europe 
North America 
Erythromycin Antibiotic 
 
10
b
 
<0.5-20 
<28-52 
2-438 
UK 
Mainland Europe 
North America 
Oxytetracycline Antibiotic 
 
10
b
 
- 
<12-37 
- 
UK 
Mainland Europe 
North America 
a
occurence data taken from: UK-[20] Mainland Europe-[17] North America-[21-22], 
b
UK Chemicals 
Investigation Programme [19], 
c
[12]  
KEY: NSAID, non steroidal anti-inflammatory drug 
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2. Analytical strategies for fate evaluation 
Prior to laboratory work, the first step for drug determination in wastewaters is sampling. This 
process is fundamental to any strategy for monitoring, and careful consideration of sampling 
equipment, sample handling and types of samples is needed. It is beyond the scope of this 
review to examine further; however an excellent overview of sampling strategies has been 
given by Ort et al [28-29].  Nevertheless, it is important to highlight that to fully understand 
fate during wastewater treatment, determination in both aqueous and particulate phases of 
wastewaters is essential [9, 30]. 
 
Trace determination of drugs in aqueous wastewater fractions (typically 0.45 µm filtered) 
requires an enrichment step followed by chromatographic separation and mass spectrometry 
(MS) detection.  Sample pre-concentration and clean up commonly involves solid phase 
extraction (SPE), and can be undertaken off-line (using extraction systems not linked to 
analytical equipment) or on-line, where extraction and quantification are automated and 
linked together.  Off-line analysis tends to use up to 1 litre of sample, and Gros et al [31] 
investigated the efficacy of various SPE sorbents (Oasis HLB, Oasis MCX, Isolute C18 and 
Isolute ENV+) for the simultaneous extraction of 13 pharmaceutical drugs of varying 
physicochemical composition.  The Oasis HLB sorbent (polystyrene-devinylbenzene-N-
vinylpyrrolidone terpolymer) [32] (without pH adjustment) exhibited superior performance, 
utilising both hydrophilic and lipophilic retention mechanisms.  Consequently, a full suite of 
drugs (up to 90) can be extracted simultaneously off-line using this sorbent [17-18, 25, 33].  
The introduction of fully automated methods further reduces sample processing restrictions 
[34-35].  At present these are emerging techniques whose use are not widespread.  Their 
reproducibility and ability to use smaller total sample volumes mean they will supersede 
traditional labour intensive SPE protocols in commercial laboratories in the future.  Drug 
determination in the particulate phase of wastewaters is not routinely monitored but those 
methods which do, use ultrasonic solvent extraction (USE) [36] or most commonly, 
accelerated solvent extraction (ASE) [30, 37-40].  The application of pressure enables the use 
of extraction solvents (eg methanol) at temperatures much higher than their boiling point, 
increasing solubility and mass transfer [41].  Following extraction the solvent can be diluted 
in water to <5 % (v/v) and subjected to SPE as an aqueous fraction [38-39].  
 
Gas chromatography-mass spectrometry is well established for quantification of chemicals in 
environmental samples, achieving method quantitation limits (MQLs) ≤10 ng l-1 for some 
drugs [42-43].  However, derivatization of more polar drugs with toxic chemicals is required 
prior to analysis to improve volatility, thermal stability and sensitivity of detection, increasing 
cost and time of sample preparation.  A further disadvantage is the run time required for 
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analysis; often up to 1 hour per sample [42-43].  This has been a rate limiting step of such 
research in the past, severely restricting sample numbers which can be analysed.  Despite 
these limitations, methods report the ability to simultaneously measure ≥63 drugs of varying 
therapeutic class from a single injection by GC-MS following derivatization [44-45].  The use 
of LC coupled to tandem MS detection (MS/MS) improves sample throughput without the 
need for additional sample preparation [46].  Furthermore, the introduction of UPLC offers 
additional reductions in run times, whilst improving sensitivity over conventional LC [23].  
For UPLC, run times are generally less than 10 minutes with MQLs <100 ng l
-1
 for most 
drugs [17-18, 25].  However, a well known problem of environmental sample analysis by LC-
MS, with electrospray ionisation (ESI) source particularly, is the quenching influence 
(ionisation suppression) of sample matrix on analyte signal strength [23, 47].  The 
commercial availability of deuterated surrogates now offers substantial improvements in 
minimizing the impact of matrix interferences, improving accuracy of analysis and up to 50 
isotopic labelled standards are used in some multi-residue methods [35].    
 
The selection of MS/MS detector type is critical for analysis type (i.e., qualitative or 
quantitative). Quantitative analysis commonly employs a triple quadrupole (QqQ) due to its 
high sensitivity.  The use of hybrid detectors such as quadrupole time of flight (QqTOF) 
offers the ability to screen and identify unknown degradation products/metabolites.  Its full 
scan sensitivity, high selectivity and specificity enable structural elucidation of non-target 
species [32].  This is a significant advance in the determination of drug fate where 
degradation products in both biological and chemical processes are formed; enabling 
degradation pathways to be identified.  However, data processing can be time consuming due 
to the lack of searchable libraries, often requiring manual spectral interpretation [32, 46].  A 
further disadvantage of TOF detection is it generally offers lower sensitivity (3 to 5 times) 
than conventional MS/MS such as QqQ [48].  Thus, the ever increasing requirement to reduce 
MQLs for trace analysis confines its use to qualitative fate evaluation.  Alternatively, hybrid 
linear ion trap (LIT) Orbitrap instrumentation offers high sensitivity for environmental 
quantitation (as offered by QqQ) and the ability to perform accurate mass determinations for 
drug identification (as offered by TOF) [46].  Although Orbitrap technology has been used to 
screen environmental samples for unknowns [49], unequivocal confirmation of degradation 
products observed by non-target MS/MS screening requires a complementary analytical 
technique or use of analytical reference standards [50].  However, as degradation products are 
often not known, there is a subsequent lack of standards for these.  Further opportunities are 
offered by Fourier transform-MS which demonstrates unrivalled mass accuracy, rapid data 
collection, good dynamic range and, high sensitivity and resolution.  However, the high cost 
of such instrumentation limits its widespread application.   
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Overall, recent trends for drug determination in wastewaters tend to use a single stage Oasis 
HLB off-line SPE followed by UPLC with detection by QqQ [17, 25, 33] or LIT [18] (Table 
3).  These methods are well suited for the determination of multiple drugs in the aqueous 
phase of crude wastewaters and secondary effluents where their concentrations are relatively 
high.  However, monitoring EE2 at environmentally relevant levels requires devoted clean up 
protocols which can be laborious due to its inherently lower concentrations [23].  
Nevertheless, there is a lack of particulate phase analysis undertaken and the concentrations 
present in tertiary effluents continue to pose an analytical challenge.   
      
3. Drug removal by conventional wastewater treatment; the current problem 
Activated sludge is an extensively implemented secondary wastewater treatment process, 
effective for carbonaceous material removal and can be adapted for nutrient removal. 
Removals of many drugs (and other chemicals of anthropogenic origin) are also observed [6-
7].  Removal of drugs and other hazardous chemicals during treatment is attributed to 
biological degradation and sorption onto biomass [52-54].  Pharmaceutical drugs have low 
vapour pressures and pKa’s ranging from 3 to 10 (Table 1) restricting any removal by 
volatilization.  The relative resistance to biodegradation and/or sorption of some drugs makes 
enhancing removal by such processes difficult.  Ibuprofen, diclofenac and carbamazepine 
encompass extremities in susceptibility to biodegradation and sorption.  These represent drugs 
reasonably amenable to sorption and biodegradation (ibuprofen), sorption only (diclofenac) 
and neither sorption or biodegradation (carbamazepine), respectively.  Consequently, removal 
differs between one another during activated sludge treatment [6-7].  Solids retention time 
(SRT) (which is proportional to the food: micro-organism (F:M) ratio) is the simplest way of 
manipulating existing activated sludge operation in the short term and, is considered critical to 
the removal of non-drug derived hazardous chemicals [6-7, 27].  An increased SRT (>10 
days) is often cited as the condition required to achieve greatest hazardous chemical removal 
[6-7] but has little effect to removals of these drugs (Figure 1, Table 4).  Generally, diclofenac 
is removed by ≤50 % and any carbamazepine removal is negligible.  Negative drug removals 
are also observed during treatment and are considered attributable to the deconjugation of 
metabolites present in the crude stream [26].  Conjugates and intermediate chemicals tend to 
go undetermined by current analytical approaches.  Parent drugs are often above their 
legislative targets for consent in secondary effluents despite accounting for typical dilution 
ratios in the environment [19].  Source control would limit drug entry into wastewater, similar 
to what has been achieved with nonylphenol [23].  Without the availability of substitute 
drugs, less persistent and with a less burdensome environmental impact, this will not be 
achievable.  However, the possibility of separate treatment of urine
Table 3. Recently validated LC-MS/MS methods applied for the quantitation of drugs in environmental matrices 
No. of 
drugs 
Sample SPE Chromatography Detector 
Run 
time / 
min
-1
 
SE 
recovery 
/ % 
SE MQL 
/ ng l
-1
 
No. of drugs quantified in 
methods application Method 
benefits 
Method 
limitations 
Ref. 
Crude 
WW 
SE TE SW 
81 Aq. Oasis HLB UPLC QqLIT 
4
a
 
7
b
 
22-146 0.6-51 57
c
 59 28 45 √ XX  [18] 
47 Aq. Oasis HLB UPLC QqQ 10 49-127 0.8-170 - 37 - 31 √ X [25] 
74 Aq. Oasis HLB UPLC QqQ 
8
a
 
5
b
 
0-174 0.1-378 - - - 73 √ 
X 
 XX 
[17] 
90 Aq. Oasis HLB HPLC QqQ 25 5-246 0.1-78 - 63 - - √ X [33] 
33
d
 Aq. 
Oasis HLB 
+ 3 sorbents 
HPLC QqQ 36
e
 64-166 2.3-186 - - - 16 
√√ 
√√√ 
X [35] 
87 Aq. 
TurboFlow 
column 
HPLC QqQ 22
e
 12-345 0.1-164 - - - 44 
√ 
√√  
√√√ 
X 
XX 
[34] 
14 Part. Oasis HLB HPLC QqQ - 70-120 0.6-19
f,g
 - 11
g
 - - √√√√ X [40] 
60 Part. Oasis MCX UPLC QqQ 20 7-142
e
 0.1-20
f,g
 30
f
 - - - √ X [30] 
5 
Aq. 
Part. 
MIP HPLC QqQ 25 
95-105 
77-91 
4-12 
4-10
f,i
 
- 5
j
 - 4
f,i
 √√√√ 
X 
XXX 
[51] 
1
k
 
(EE2) 
Aq. 
Part. 
C18, NH
2 
Silica, NH
2
 
UPLC QqQ 9 
96
 
97 
0.06
 
2.96
f
 
1 1 - - 
√√√√ 
√√√√√ 
X 
XXXX 
[23] 
a
positive ionisation mode
 b
negative ionisation mode
 c
application is not a sequential train of processes 
 d
includes additional 55 chemicals in method
 e
includes on-line SPE time 
f
ng g
-1  g
de-watered sludge
 h
settled sewage
 i
sediment 
j
aqueous only 
k
includes 4 natural estrogens in method 
Key: MQL, method quantitation limit; SPE, solid phase extraction; SE, secondary effluent, WW, wastewater; TE, tertiary effluent; SW, surface water; Aq., aqueous; Part., 
particulate; QqLIT, linear ion trap; QqQ, triple quadrupole; MIP, molecularly imprinted polymer; √, high number of drugs varying in physio-chemical composition; √√, 
includes some known degradation products; √√√, fully automated, small sample requirements; √√√√, high recoveries for all drugs measured; √√√√√, very low MQL; X, 
application to real samples limited; XX, numerous drugs reported <MQL; XXX, limited to drugs of specific physio-chemical composition; XXXX, extensive sample pre-
treatment required 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Removals of ibuprofen (■, n=36), diclofenac (□, n=19) and carbamazepine (▲, n=25) by 
activated sludge operating at varying solids retention time.  Ibuprofen, diclofenac and 
carbamazepine represent drugs reasonably amenable to sorption and biodegradation, sorption 
only and neither sorption or biodegradation, respectively.  Inset, octanol-water coefficients, 
partition coefficients and degradation rate constants – a[16] b[53]   
(removal data obtained from: [6-7, 26, 55-62] – Table 4, no data reported as <MDL) 
 
 
streams may be an effective solution in some circumstances [63].  Additionally, membrane 
bioreactor systems generally achieve greater drug removals than conventional secondary 
processes [32, 60-61].  Without their application, the remaining alternative to enhance drug 
removal is the addition of a tertiary process or processes to an existing conventional 
secondary treatment asset (e.g., activated sludge).  This requires a process not excessively 
space consuming and can treat secondary effluents at relatively short contact times.  Some 
available options suiting these criteria include; biofiltration (sand or trickling filters), 
chemical (ozone) and adsorption (granular activated carbon) processes.  The fate and removal 
of drugs differ substantially between these systems.         
 
4. Drug fate and removal in tertiary processes  
4.1. Biologically active sand filters 
Drug removal by biofiltration processes (tertiary sand or trickling filters) is by physical and 
biological mechanisms.  Total removals by sand filters vary from 2 % for carbamazepine to 
>95 % for ibuprofen [64] (Figure 2, Table 5), similar to those achieved by activated sludge.  
Despite treating different wastewaters of differing composition, activated sludge and tertiary 
sand filters essentially rely on the same mechanisms.  Sand filters depend on a fixed biofilm 
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Table 4. Removal of ibuprofen, diclofenac and carbamazepine in activated sludge at varying SRT 
 
Drug 
Flow rate / 
m3 d-1 
SRT/ d-1 
HRT/ h-
1 
MLSS / 
mg l-1 
COD / 
mg l-1 
SS conc. 
/ ng l-1 
SE conc. 
/ ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen - 0.3 - - - - - -1.0 [6] 
 - 1 - - - - - 9.0 [6] 
 626,000 1.9 7 - - 50,700 24,600 51.5 [55] 
 - 2 1.9 4,000 - 2,300 2,400 -4.2 [7] 
 47,860 2.2 13 - - 14,200 21,700 -52.8 [55] 
 185,000 2.7 12 - - 27,900 5,400 80.6 [55] 
 585,667 2.7 14 - - 58,200 6,200 89.3 [55] 
 3,967 3 10 3,030 113* - - 94.0 [26] 
 22,000 3 12 - 508.2 
13,355-
17,585 
1,420-
6,056 
82.5 [61] 
 645,000 3.8 8.6 - - 909 86.7 90.5 [58] 
 1,984 4.5 15 2,482 113* - - 94.0 [26] 
 409,000 4.6 8.0 - - 593 21.0 96.4 [58] 
 125,248 4.7 13 - - 21,800 300 98.6 [55] 
 1,199,000 5.0 7.1 - - 578 14.3 97.5 [58] 
 - 5.0 - - - - - 96.0 [6] 
 5,506 5.5 15 2,836 205* - - 95.0 [26] 
 15,300 5.5 15 1,743 154* - - 94.0 [26] 
 19,260 6 22 2,084 128* - - 98.0 [26] 
 125,000 7 12 2,000 - 1,966 40.0 98.0 [60] 
 20,000 6-10 35 - 510-680 5,700 88.5 98.4 [62] 
 210,000 8.4 8.9 - - 595 8.0 98.7 [58] 
 68,498 9.6 15 - - 27,300 2,700 90.1 [55] 
 - 9.6 - - - - - 92.0 [6] 
 17,994 10.5 13 2,105 51* - - 91.0 [26] 
 - 10-12 7.3 - - - - 91-99 [56] 
 366,898 12.6 23 - - 39,100 50.0 >99.9 [55] 
 60,000 12-14 22 
5,000-
6,000 
- 6,242 194 97.0 [57] 
 11,783 13 13.5 2,740 143-160 - - 86.0 [59] 
 - 17.0 - - - - - 99.0 [6] 
 - 22-24 16.8 - - - - 96-98 [56] 
 - 23.6 - - - - - 98.0 [6] 
 - 24.0 - - - - - 99.0 [6] 
 - 35.0 - - - - - 99.0 [6] 
 5,074 35.3 27 - - 58,900 50.0 >99.9 [55] 
 - 46 28.8 3,100 - 1,200 24.0 98.0 [7] 
 - 52 326 4,000 - 2,448 20.0 99.2 [7] 
Diclofenac - 1.0 - - - - - 0.0 [6] 
 - 2 1.9 4,000 - 1,400 1,300 7.1 [7] 
 3,967 3 10 3,030 113* - - 28.0 [26] 
 105,300 5 16 2,450 127* - - 22.0 [26] 
 - 5.0 - - - - - 36.0 [6] 
 5,506 5.5 15 2,836 205* - - -88.0 [26] 
 15,300 5.5 15 1,743 154* - - -103 [26] 
 19,260 6 22 2,084 128* - - 30.0 [26] 
 20,000 6-10 35 - 510-680 100 485 -79.4 [62] 
 - 9.6 - - - - - 9.0 [6] 
 17,994 10.5 13 2,105 51* - - -143.0 [26] 
 - 10-12 7.3 - - - - 22-33 [56] 
 - 17.0 - - - - - 13.0 [6] 
 - 22-24 16.8 - - - - 30-34 [56] 
 - 23.6 - - - - - 13.0 [6] 
 - 24.0 - - - - - 52.0 [6] 
 4,554 30 23 4,554 178* - - 77.0 [26] 
 - 35.0 - - - - - 3.0 [6] 
 - 46 28.8 3,100 - 905 780 13.8 [7] 
 - 52 326 4,000 - 3,190 1,680 47.3 [7] 
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Table 4 (continued) 
Drug 
Flow rate / 
m3 d-1 
SRT/ d-1 
HRT/ h-
1 
MLSS / 
mg l-1 
COD / 
mg l-1 
SS conc. 
/ ng l-1 
SE conc. 
/ ng l-1 
Removal 
/ % 
Ref. 
Carbamazepine - 0.3 - - - - - 0.0 [6] 
 17,364 0.9 12 - - 1,300 800 38.5 [55] 
 - 1.0 - - - - - -9.0 [6] 
 626,000 1.9 7 - - 800 700 12.5 [55] 
 - 2 1.9 4,000 - 670 690 -3.0 [7] 
 47,860 2.2 13 - - 1,100 2,300 -109.1 [55] 
 185,000 2.7 12 - - 1,200 1,700 -41.7 [55] 
 585,667 2.7 14 - - 600 800 -33.3 [55] 
 645,000 3.8 8.6 - - 55.9 32.1 42.6 [58] 
 6,243 4.1 14 - - 1,000 500 50.0 [55] 
 409,000 4.6 8.0 - - 43.1 46.9 -8.6 [58] 
 125,248 4.7 13 - - 700 800 -14.3 [55] 
 1,199,000 5.0 7.1 - - 50.5 45.4 10.2 [58] 
 - 5.0 - - - - - 6.0 [6] 
 210,000 8.4 8.9 - - 173 117 32.4 [58] 
 68,498 9.6 15 - - 700 700 0.0 [55] 
 - 9.6 - - - - - 9.0 [6] 
 - 10-12 7.3 - - - - 0-18 [56] 
 366,898 12.6 23 - - 900 1,700 -88.9 [55] 
 - 17.0 - - - - - -11.0 [6] 
 - 22-24 16.8 - - - - 0-5 [56] 
 - 35.0 - - - - - 1.0 [6] 
 5,074 35.3 27 - - 1,000 900 10.0 [55] 
 - 46 28.8 3,100 - 325 426 -31.1 [7] 
 - 52 326 4,000 - 704 952 -26.1 [7] 
SRT, solids retention time; HRT, hydraulic retention time; MLSS, mixed liquor suspended solids; 
COD, chemical oxygen demand; SS, settled sewage; SE, secondary effluent 
*Biological oxygen demand 
 
 
 
 
 
 
Figure 2. Removals of ibuprofen, diclofenac and carbamazepine reported in the literature for 
biofiltration, chemical and adsorption processes.  Ibuprofen, diclofenac and carbamazepine 
represent drugs reasonably amenable to sorption and biodegradation, sorption only and neither 
sorption or biodegradation, respectively (removal data obtained from: [64-75] - Table 5, 6 and 7) 
a
1/3 removed <MQL 
b
2/3 removed <MQL 
c
3/4 removed <MQL 
d
4/5 removed <MQL 
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Table 5. Removal of drugs from environmental waters by biofiltration processes 
Drug Proce
ss 
Temp.°
C 
HRT 
h-1 
Wastewate
r type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen SF - 4-6 Municipal - 11,700a 1,170 90 [67] 
 SF - 0.3 River - 276 <14 >95 [64] 
 SF - 1 Municipal ASP - - 73b [68] 
Diclofenac SF - 4-6 Municipal - 820a 197 76 [67] 
 SF - 0.3 River - 252 181 28 [64] 
 SF 22 2 Municipal - - - 23 [73] 
Carbamazepin
e 
SF - 4-6 Municipal - 2,060a 1,833 11 [67] 
 SF - 0.3 River - 85 84 2 [64] 
 SF - 1 Municipal ASP - - 22b [68] 
Naproxen SF - 4-6 Municipal - 1,570a 314 80 [67] 
 SF - 0.3 River - 170 24 86 [64] 
 SF - 1 Municipal ASP - - 32b [68] 
Ketoprofen SF - 1 Municipal ASP - - 16b [68] 
EE2 SF - 0.3 River - 316 246 22 [64] 
 SF 18 - Municipal ASP - 0.2 82 [76] 
 SF - - Municipal ASP - - 7 [77] 
 SF - - Municipal OD - - 9 [77] 
 SF 22-25 - Municipal - 109 64 41 [78] 
Erythromycin SF - 0.3 River - 104 75 28 [64] 
 SF 19-22 0.4 Municipal ASP - - 20 [79] 
 
 
comprised of a diverse community of micro-organisms embedded within a matrix of 
extracellular polymeric substances (EPS) consisting of proteins, nucleic acids, 
polysaccharides and amphiphilic polymeric compounds [81].  The composition of EPS shifts 
with biofilm age [81], and is known to influence EE2 uptake [54].  The high tendency of 
some drugs to partition to solid organic matter, similar to biofilms has been confirmed by 
ASE followed by LC-MS/MS analysis [30, 38-40].  Those hydrophobic drugs with a 
comparatively high log Kow (>4) (e.g., diclofenac and fluoxetine) are considered to have a 
tendancy to sorb to solid organic surfaces such as biofilms [82-83].  However, sorption cannot 
be predicted by hydrophobicity alone [83-84]; other properties such as molecular weight and 
ionic speciation are of known importance [83], as is the nature of other dissolved species with 
which they may interact [85].  Extracellular polymeric substances offer both anionic and 
cationic functional groups for the exchange of charged species [83].  At a pH typical of 
municipal wastewaters (e.g., 7-8), EPS is negatively charged [83] with pKa’s generally 
ranging from 6.2 to 10.1 [86].  Those drugs whose pKa is <7 (e.g., ibuprofen, diclofenac,  
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Figure 3.  Biological degradation products (DP) of diclofenac (A, adapted from [90]) and the 
proposed biotransformation pathway of bezafibrate (B, adapted from [50])  
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naproxen, ketoprofen and oxytetracyline) (Table 1) will themselves be negatively charged and 
repulsion with the biofilm may restrict sorption.  Removal will also be influenced by biofilm 
porosity.  Drugs whose molecular size is comparatively large (e.g., erythromycin), will have a 
reduced rate of mass transfer between the liquid medium and the biofilm, limiting partitioning 
[83].  Drugs which are comparatively smaller (<300 g mol
-1
) and relatively hydrophobic in 
nature (log Kow’s >3) (e.g., ibuprofen, diclofenac, naproxen, ketoprofen, propranolol and EE2, 
Table 1) are expected to partition well within the biofilm matrix.   
 
Sorption is also considered to be an intermediate step in biodegradation [52, 54].  Assuming 
similar behaviour to EE2 and other hazardous chemicals in biological processes, drug 
biodegradation is likely to be mediated on the surface and/or within intact bacterial cells [52, 
54, 87].  Free ammonia mono-oxygenase enzymes released by lysis extracellularly are not 
likely to be involved in biodegradation [52, 87]. Gaulke et al [88] observed that EE2 removal 
in nitrifying batch studies was not by nitrifying bacteria activity, dismissing the hypothesis 
that nitrification augments EE2 removals [89].  The synthesis of nitro-EE2 confirmed that 
EE2 is nitrated at high ammonia feed concentrations caused by the high production of 
nitrates; EE2 removal here is an artefact of laboratory scale investigation.  Biodegradation at 
environmentally representative conditions is by heterotrophic micro-organisms, capable of 
scavenging a broad range of organic material [87].  Interestingly, differences in 
biodegradation are observed for drugs which sorb similarly to biomass (e.g., ibuprofen and 
diclofenac, Figure 1) suggesting chemical structure controls susceptibility to biological attack.  
The structure of ibuprofen is comparatively simpler than that of diclofenac (i.e., single 
aromatic ring and non-halogenated, Table 2) which may aid its biodegradation.  Drugs of 
increasing structural complexity and elemental diversity such as antibiotics (e.g., ofloxacin, 
erythromycin and oxytetracycline) may be less favourable to biodegradation especially 
considering their possible toxicity to bacteria.  However, ‘biodegradation’ here is not 
indicative of complete mineralisation. Drugs rich in functional groups provide more possible 
sites for biological attack, inducing a change to the parent structure.  Kosjek et al [90] 
investigated the degradation products of diclofenac, utilising Oasis HLB SPE and UPLC 
separations to ensure adequate sensitivity required by QqTOF.  In full scan mode the total ion 
chromatogram (TIC) was screened and a protonated compound was then selected for further 
product ion scans [90].  Accurate mass measurements and in-source fragmentation enabled 
chemical structure elucidation of three biotransformation products (Figure 3A).  Similarly 
Helbing et al [50] used LIT-Orbitrap MS to identify five degradation products of bezafibrate 
(Figure 3B).  The dehydrogenation product (DP1) is structurally similar to the parent drug 
indicating it may behave similarly in the environment. 
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4.2. Chemical oxidation  
Titanium dioxide photocatalysis [91] and Fenton chemistry (i.e., catalytic oxidation of 
hydrogen peroxide) [92] have been applied to water treatment however ozone is the most well 
established and studied of the chemical processes for drug removal.  Ozone treatment 
enhances the removal of all drugs including carbamazepine where removals of ≥96 % are 
observed [65, 70-71, 73-74] (Figure 2, Table 6).  However, typical ozone doses applied 
during water treatment often do not enable full mineralization of drugs [93], likely to be 
caused by the clouding influence of the matrix.  Wastewaters contain relatively high 
concentrations of bulk organics which can shield targeted chemicals from removal, quenching 
the ozone dose.  Furthermore, Huber et al [93] observed that following removal of EE2 from 
clean water by a high ozone dose, a slow re-appearance of the drug (0.1-0.5 % of the initial 
concentration) occurred.  It is hypothesized that some EE2 is in the form of hydroperoxides 
which are not readily reactive to ozone.  This could be greater in wastewater where clouding 
will reduce reaction kinetics and this will hinder the complete mineralisation of the parent 
drug.  Degradation by ozonation can occur selectively by direct ozone attack itself and non-
selectively by hydroxyl radicals formed upon ozone decay [93].  Ozone reacts rapidly with 
phenols at neutral or basic pH [94] therefore it will readily attack the phenolate anion of EE2 
and oxytetracycline.  It also selectively attacks amines and double bonds of aliphatic 
chemicals [95].  The chemical structure of all the drugs considered here (except ibuprofen) 
are highly susceptible to direct ozone attack (Table 2).  Hydroxyl radicals are less selective 
and react with a range of chemical functional groups.  The non-selective behaviour of the 
hydroxyl radicals can induce complex reaction pathways [93].  Numerous authors observed 
high removals of various drugs by ozone treatment, often to concentrations below their MQLs 
[65, 70-71].  However, complete removal of the parent drug does not necessarily represent 
removal of toxicity.  Structurally similar degradation products of potential toxicity can be 
formed and remain undetected using conventional MS/MS (i.e., QqQ).  A large number of 
degradation products for various drugs have been observed [93, 96].  Non-target screening of 
ozone treated water enabled determination of 17 degradation products of diclofenac [96] 
(Figure 4).  The majority of these products are structurally similar to the parent drug 
indicating similar behaviour in the receiving environment.  Again these were identified by 
Oasis HLB extraction and QqTOF detection.  Accurate mass spectra were collected at mass to 
charge (m/z) ratios >50 encompassing all degradation products of notable size.     
 
4.3. Adsorption by activated carbon 
Activated carbon often contained in a packed bed or filter is a highly porous medium offering 
a large internal surface area for sorption to take place.  Performance is dependant on activated 
carbon properties (e.g., pore size, surface charge) and solute characteristics (e.g., shape, size) 
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Table 6. Removal of drugs from environmental waters by ozone treatment 
Drug Process 
Chemical 
dose 
HRT 
h-1 
Wastewater 
type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Remova
l / % 
Ref. 
Ibuprofen Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 130 <50 >62 [65] 
 Ozone 2 mg l-1 0.2 
Surface 
waters 
- - - 40-77 [75] 
 Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - >46a [68] 
Diclofenac Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 2,000 <10 >99 [71] 
 Ozone 3 mg l-1 0.3 Municipal - - - 92 [73] 
 Ozone 50 µM <0.1 Municipal - 433 <1 >99 [70] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 1,300 <50 >96 [65] 
Carbamazep
ine 
Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 900 <1 >99 [71] 
 Ozone 3 mg l-1 0.3 Municipal - - - 96 [73] 
 Ozone 130 µM 0.1 Municipal - 106 <1 >99 [70] 
 Ozone 1 mg l-1 - Municipal GAC 67 1 99 [74] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 2,100 <50 >98 [65] 
Naproxen Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - >99a [68] 
 Ozone 
10-15 mg 
l-1 
0.3 Municipal ASP 100 <50 >50 [65] 
Bezafibrate Ozone 
0.6 g O3 g 
DOC0
−1 
- Municipal ASP 1,500 345 77 [71] 
 Ozone 340 µM 0.3 Municipal - 115 4 97 [70] 
 Ozone 2 mg l-1 0.2 
Surface 
waters 
- - - >98 [75] 
Fluoxetine Ozone 50 µM <0.1 Municipal - 17 <2 >88 [70] 
Ketoprofen Ozone 3 mg l-1 0.5 Municipal 
ASP + 
SF 
- - 73a [68] 
 
[69].  Preferential attraction to the activated carbon surface is by hydrogen bonding and 
London forces creating a strong binding affinity.  Even moderately hydrophobic chemicals 
(log Kow >2) have a high propensity to removal [95].  The availability of some drugs as anions 
causes them to be attracted to the carbon surface.  As a result substantial removals of 
hydrophobic and hydrophilic drugs have been observed by granular activated carbon (GAC) 
[66, 73-74] (Figure 2, Table 7).  Carbamazepine removals up to 97 % have been achieved 
[73].  Despite the very hydrophilic nature of oxytetracycline (Table 1), its large molecular size 
is likely to be entrapped within the highly porous structure of the activated carbon.  At full-
scale treatment processes low removals have been observed for some drugs; ibuprofen (16 %) 
[69], carbamazepine (16-23 %) [69, 72] and propranolol (17 %) [72] (Table 7).  The quality 
of the secondary effluent will have a significant influence on the performance of GAC 
through the competition for available sorption sites [69].  The frequency of 
replacement/regeneration of the activated carbon medium is another controlling factor to its 
success, especially whilst treating wastewaters comprising relatively high concentrations of 
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bulk organics.  This may account for large variations in drug removals observed between 
processes.  Chiu et al [97] demonstrated the possibility of in situ catalytic regeneration of 
GAC using iron nano-catalysts.  This could provide an effective means of regeneration in the 
future, limiting variations in performance currently observed.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Degradation intermediates formed by ozone treatment of diclofenac and proposed 
degradation pathways (adapted from [96]) 
 
 
 
5. Future trends 
Secondary effluents typically demand analytical MQLs in the low ng l
-1
 range to determine 
most drugs.  Reported analytical methods are well suited for determining drugs in the aqueous 
phase of secondary effluents.  To demonstrate, no data in Figure 1 (and Table 4) was reported 
below MQL (n=80).  Despite proposed legislative targets being applied to the aqueous phase  
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Table 7. Removal of drugs from environmental waters by adsorption processes 
Drug Process 
HRT 
h-1 
Wastewater 
type 
Upfront 
process 
SE. 
conc. / 
ng l-1 
TE 
conc. / 
ng l-1 
Removal 
/ % 
Ref. 
Ibuprofen GAC 0.3 Municipal ASP 64 <10 >84 [74] 
 GAC - Raw water - 23 <1 >96 [66] 
 GAC - Surface water - 1.1 <1 >10 [69] 
 GAC - - SF 8,760 7,325 16 [69] 
Diclofenac GAC 0.3 Municipal ASP 99 <10 >90 [74] 
 GAC - Municipal ASP - - >98 [72] 
 BAC 2 Municipal MBR - - 92 [73] 
 GAC - - SF 3.2 <1 >69 [69] 
Carbamazepine GAC 0.3 Municipal ASP 250 67 73 [74] 
 GAC - Municipal ASP - - 23 [72] 
 BAC 2 Municipal MBR - - 97 [73] 
 GAC - Raw water - 8 <1 >87 [66] 
 GAC - Surface water - 2.2 <1 >55 [69] 
 GAC - - SF 199 168 16 [69] 
Propranolol GAC - Municipal ASP - - 17 [72] 
EE2 GAC - Municipal ASP - - >43 [72] 
Erythromycin GAC 0.3 Municipal ASP 270 28 90 [74] 
 BAC 2 Municipal MBR - - 92 [73] 
HRT, hydraulic retention time; SE, secondary effluent; TE, tertiary effluent; ASP, activated sludge 
plant; GAC, granular activated carbon; BAC, biologically activated carbon; MBR, membrane 
bioreactor 
 
 
of wastewaters (i.e., a pre-filtered sample); suspended solids can provide a pathway to their 
release into the environment [30].  Their determination in the particulate phase is also 
essential for fate evaluation.  Suspended solids are ubiquitous to wastewaters and can vary 
spatially and temporally.  Particulate bound drugs often go undetermined (Table 3), owing to 
the complexity of the matrix and the additional analytical requirements it demands.  The 
proposed requirement to undertake particulate phase analysis to determine drug fate is most 
pertinent to secondary processes which receive relatively high concentrations of suspended 
solids.  The relatively hydrophobic nature of some drugs can cause them to partition well to 
solids.  For example crude wastewaters can contain >50 % of fluoxetine bound to particulates 
[30].  Monitoring here enables complete process mass balances to be determined, aiding fate 
and performance understanding.  Particulate fate understanding may indicate a clouding 
influence during treatment which limits removal.  Activated sludge sorption and 
biodegradation may be restricted for drugs associated with particulates in the receiving 
wastewater.  This could lead to conventional process optimisation to enhance drug removal.  
For example, the use of micro-screens in place of conventional primary sedimentation tanks 
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could enhance particulates removal from the crude stream.  However, there is a substantial 
gap between drug concentrations achieved by the current operations of existing secondary 
assets and proposed legislative targets [19] (Table 2, Table 4).  Therefore there is an expectant 
need for tertiary treatment technologies to target these specific chemicals.    
 
Tertiary treatment processes enhance drug removal, significantly reducing effluent 
concentrations.  To fully ascertain tertiary process performance, analytical methods require 
MQLs <10 ng l
-1 
[64, 70-71, 74], and ideally <1 ng l
-1
 [66, 69-71] (Tables A2-4).  This poses a 
further analytical challenge as such concentrations cannot be ascertained for the majority of 
drugs with current MQLs.  To illustrate, concentrations of the representative drugs; ibuprofen, 
diclofenac and carbamazepine in sand filtration, ozone and activated carbon treated effluents 
were reported below MQL in 49 % of cases (n=35) (Figure 2).  Despite these being below 
proposed legislative targets for most drugs (Table 2), monitoring at these concentrations is 
needed as the cumulative toxicological effect of drugs is not known.  This could result in a 
future reduction in legislative requirements.  To illustrate, the previous EE2 predicted no 
effect concentration (PNEC) in the UK was 0.1 ng l
-1
 [98].  The proposed EQS is now 0.035 
ng l
-1
 following its classification as a priority hazardous chemical [12].  This has created a 
serious analytical burden as such concentrations are now beyond current analytical 
capabilities [23].  Lowering current MQLs is also needed to assess breakdown reaction 
completeness.  The first stage of this is to determine parent drug removal.  Further 
investigation of specific breakdown mechanisms to understand the criticality between parent 
drug final concentration, and degradation product production is needed.  Methodologies to 
quantify the full range degradation products will be restricted in the short term by the lack of 
unique reference standards available for these.  However, the identification of numerous 
degradation products in both biological and chemical processes has brought attention to their 
presence and created a demand for their commercial availability (Figures 3-4).  The 
complimentary use of biological assays would improve understanding of the synergistic 
toxicological effect of multiple drugs and their degradation products at low concentration.  
Process design and operation must integrate the removal of these intermediates which can be 
of greater concern than the parent chemical due to their subsequent transformation to more 
toxic chemicals in the environment [47].     
 
Lowering drug MQLs requires existing analytical method optimisation.  The low recoveries 
(<50 %) typically stipulated prior to internal standard correction [25], can be improved to 
reduce the achievable MQL.  Baker and Kasprzyk-Hodern [99] gave an excellent account of 
sample preparations parameters which can influence recovery.  For example drugs can be 
adsorbed onto glassware surfaces during handling and processing.  Using silanized SPE 
 20 
extract vials gave recoveries six times higher than non-silanized vials for some drugs.  All 
glassware used during sample collection and processing requires silanization to ensure 
maximum recoveries.  Silanization of glassware is not mentioned in the procedures of most 
reported analytical methods [17-18, 25, 33].  Improving chromatographic separations could 
also significantly increase detection capabilities. Incorporating a large number of drugs into a 
single short UPLC run (<10 minutes) results in a number of co-eluting peaks [17-18, 25].  
Despite the use of mass scanning windows which typically range from 0.3 to 2 minutes in 
length for UPLC separations [17-18], sensitivity can be lost whilst simultaneously scanning 
for a number of transitions registered at the same time [17].  To demonstrate, Gros et al [18] 
reports up to 10 drugs co-eluting within a 0.1 minute time period with scanning windows of 
0.5 minutes.  Thus, only monitoring for one drug (of most criticality) in this time period could 
increase sensitivity and notably reduce the MQL.   
 
Tertiary processes receive secondary effluents comprising comparatively high concentrations 
of dissolved organics (e.g., colloids).  However, knowledge of drug behaviour in the charged 
colloidal fraction of wastewater is limited.  Shen et al [100] successfully showed humic acid, 
a small molecular weight charged species could effectively retain the hormone, estrone in 
solution.  This can restrict sorption in tertiary processes characterised by very short contact 
times.  Furthermore, the complexity of the colloidal fraction and its interaction with the drugs 
could also lead to incomplete breakdown reactions in both biological and chemical processes.  
A fractionation step during sample pre-treatment to separate dissolved colloids by molecular 
weight will aid this.  It is postulated that drugs will preferentially be in specific size fractions.  
This is likely to vary between drugs due to the range of physicochemical behaviour they 
exhibit.  Understanding drug fate in the colloidal fraction of wastewater is essential for 
tertiary process selection, diagnosis and optimisation.      
 
6. Conclusion 
Advances in both quantitative and qualitative determinations of pharmaceutical drugs have 
aided the understanding of their occurrence and fate during wastewater treatment.  A robust 
understanding of tertiary process performance is now needed by improving analytical focus.  
An appropriate treatment strategy could then be implemented to ensure adequate protection of 
the aquatic environment is achieved.  
 
Acknowledgements 
B.P. is grateful to the U.K. Engineering and Physical Sciences Research Council (EPSRC) for 
the award of a PhD scholarship.  We would like to thank the following UK Water Companies: 
 21 
Northumbrian Water, Anglian Water, Severn Trent Water, Yorkshire Water and United 
Utilities for providing their support and funding.   
 
References 
[1] N.D. Bedding, A.E. McIntyre, R. Perry, J.N. Lester, Organic contaminants in the aquatic 
environment. I. Sources and occurrence, Sci. Total Environ. 25 (1982) 143-167. 
[2] R.S.K. Buisson, P.W.W. Kirk, J.N. Lester, Determination of chlorinated phenols in water, 
wastewater, and wastewater sludge by capillary GC/ECD, Chromatogr. Sci., 22 (1984) 339-
342. 
[3] A.M. Robertson, J.N. Lester, Supercritical fluid extraction of s-triazines and phenylurea 
herbicides from sediment, Environ. Sci. Technol., 28 (1994) 346-351. 
[4] O.A.H. Jones, N. Voulvoulis, J.N. Lester, Human pharmaceuticals in the aquatic 
environment: a review, Environ. Technol., 22 (2001) 1383-1394. 
[5] O.A.H. Jones, N. Voulvoulis, J.N. Lester, Potential impact of pharmaceuticals on 
environmental health, Bull. World Health Org., 81 (2003) 768-769. 
[6] N. Kreuzinger, M. Clara, B. Strenn, H. Kroiss, Relevance of the sludge retention time 
(SRT) as design criteria for wastewater treatment plants for the removal of endocrine 
disruptors and pharmaceuticals from wastewater, Water Sci.Technol. 50 (2004) 149-156. 
[7] M. Clara, N. Kreuzinger, B. Strenn, O. Gans, H. Kroiss, The solids retention time - A 
suitable design parameter to evaluate the capacity of wastewater treatment plants to remove 
micropollutants, Water Res. 39 (2005) 97-106. 
[8] R.L. Gomes, M.D. Scrimshaw, J.N. Lester, Determination of endocrine disrupters in 
sewage treatment and receiving waters, Trends Anal. Chem., 22 (2003) 697-707. 
[9] R.L. Gomes, E. Avcioglu, M.D. Scrimshaw, J.N. Lester, Steroid estrogen determination in 
sediment and sewage sludge: a critique of chromatographic/mass spectrometry methods 
incorporating a case study in method development, Trends Anal. Chem. 23 (2004) 737-744. 
[10] R.L. Gomes, H.E. Deacon, K.M. Lai, J.W. Birkett, M.D. Scrimshaw, J.N. Lester, An 
assessment of the bioaccumulation of estrone in Daphnia magna, Environ. Toxicol. Chem., 
23 (2004) 105-108. 
[11] European Commission. Priority Substances Daughter Directive-Directive 2008/105/EC 
of the European Parliament and of the Council of 16 December 2008 on environmental 
quality standards in the field of water policy.  2008. 
[12] European Commission. Proposal for a Directive of the European Parliament and of the 
council amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in 
the field of water policy. 2012. 
 22 
[13] J.P. Sumpter, S. Jobling, The occurrence, causes, and consequences of estrogens in the 
aquatic environment, Environ. Toxicol. Chem. 32 (2013) 249-251. 
[14] M. Galus, J. Jeyaranjaan, E. Smith, H. Li, C. Metcalfe, J.Y. Wilson, Chronic effects of 
exposure to a pharmaceutical mixture and municipal wastewater in zebrafish, Aquatic 
Toxicol. 132-133 (2013) 212-222. 
[15] T. Brodin, J. Fick, M. Jonsson, J. Klaminder, Dilute concentrations of a psychiatric drug 
alter behavior of fish from natural populations, Science. 339 (2013) 814-815. 
[16] EPI Suite. http://www.epa.gov/oppt/exposure/pubs/episuite.htm (accessed 07.01.13). 
[17] R. López-Serna, M. Petrović, D. Barceló, Development of a fast instrumental method for 
the analysis of pharmaceuticals in environmental and wastewaters based on ultra high 
performance liquid chromatography (UHPLC)-tandem mass spectrometry (MS/MS), 
Chemosphere. 85 (2011) 1390-1399. 
[18] M. Gros, S. Rodríguez-Mozaz, D. Barceló, Fast and comprehensive multi-residue 
analysis of a broad range of human and veterinary pharmaceuticals and some of their 
metabolites in surface and treated waters by ultra-high-performance liquid chromatography 
coupled to quadrupole-linear ion trap tandem mass spectrometry, J. Chromatogr. A. 1248 
(2012) 104-121. 
[19] M. Gardner, S. Comber, M.D. Scrimshaw, E. Cartmell, J. Lester, B. Ellor, The 
significance of hazardous chemicals in wastewater treatment works effluents, Sci. Total 
Environ. 437 (2012) 363-372. 
[20] B. Kasprzyk-Hordern, R.M. Dinsdale, A.J. Guwy, The removal of pharmaceuticals, 
personal care products, endocrine disruptors and illicit drugs during wastewater treatment and 
its impact on the quality of receiving waters, Water Res. 43 (2009) 363-380. 
[21] C. Wu, J.D. Witter, A.L. Spongberg, K.P. Czajkowski, Occurrence of selected 
pharmaceuticals in an agricultural landscape, western Lake Erie basin, Water Res. 43 (2009) 
3407-3416. 
[22] I. Ferrer, E.M. Thurman, Analysis of 100 pharmaceuticals and their degradates in water 
samples by liquid chromatography/quadrupole time-of-flight mass spectrometry, J. 
Chromatogr. A. 1259 (2012) 148-157. 
[23] B. Petrie, E.J. McAdam, K.H. Richards, J.N. Lester, E. Cartmell, Application of ultra-
performance liquid chromatography-tandem mass spectrometry for the determination of 
steroid oestrogens in wastewaters, Int. J. Environ. Anal. Chem. 
DOI:10.1080/03067319.2012.717272 (2012) 
[24] C. Hignite, D.L. Azarnoff, Drugs and drug metabolites as environmental contaminants: 
chlorophenoxyisobutyrate and salicylic acid in sewage water effluent, Life Sci. 20 (1977) 
337-341. 
[25] E. Gracia-Lor, J.V. Sancho, F. Hernández, Multi-class determination of around 50 
pharmaceuticals, including 26 antibiotics, in environmental and wastewater samples by ultra-
 23 
high performance liquid chromatography-tandem mass spectrometry, J. Chromatogr. A. 1218 
(2011) 2264-2275. 
[26] L. Lishman, S.A. Smyth, K. Sarafin, S. Kleywegt, J. Toito, T. Peart, B. Lee, M. Servos, 
M. Beland, P. Seto, Occurrence and reductions of pharmaceuticals and personal care products 
and estrogens by municipal wastewater treatment plants in Ontario, Canada., Sci. Total 
Environ. 367 (2006) 544-558. 
[27] E.J. McAdam, J.P. Bagnall, A. Soares, Y.K.K. Koh, T.Y. Chiu, M.D. Scrimshaw, J.N. 
Lester, E. Cartmell, Fate of alkylphenolic compounds during activated sludge treatment: 
Impact of loading and organic composition, Environ. Sci. Technol. 45 (2011) 248-254. 
[28] C. Ort, M.G. Lawrence, J. Reungoat, J.F. Mueller, Sampling for PPCPs in wastewater 
systems: Comparison of different sampling modes and optimization strategies, Environ. Sci. 
Technol. 44 (2010) 6289-6296. 
[29] C. Ort, M.G. Lawrence, J. Rieckermann, A. Joss, Sampling for pharmaceuticals and 
personal care products (PPCPs) and illicit drugs in wastewater systems: Are your conclusions 
valid? A critical review, Environ. Sci. Technol. 44 (2010) 6024-6035. 
[30] D.R. Baker, B. Kasprzyk-Hordern, Multi-residue determination of the sorption of illicit 
drugs and pharmaceuticals to wastewater suspended particulate matter using pressurised 
liquid extraction, solid phase extraction and liquid chromatography coupled with tandem mass 
spectrometry, J. Chromatogr. A. 1218 (2011) 7901-7913. 
[31] M. Gros, M. Petrović, D. Barceló, Development of a multi-residue analytical 
methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for 
screening and trace level determination of pharmaceuticals in surface and wastewaters, 
Talanta. 70 (2006) 678-690. 
[32] J. Radjenović, M. Petrović, D. Barceló, M. Petrović, Advanced mass spectrometric 
methods applied to the study of fate and removal of pharmaceuticals in wastewater treatment, 
TrAC - Trends Anal. Chem. 26 (2007) 1132-1144. 
[33] R. Grabic, J. Fick, R.H. Lindberg, G. Fedorova, M. Tysklind, Multi-residue method for 
trace level determination of pharmaceuticals in environmental samples using liquid 
chromatography coupled to triple quadrupole mass spectrometry, Talanta. 100 (2012) 183-
195. 
[34] R. López-Serna, S. Pérez, A. Ginebreda, M. Petrović, D. Barceló, Fully automated 
determination of 74 pharmaceuticals in environmental and waste waters by online solid phase 
extraction-liquid chromatography- electrospray-tandem mass spectrometry, Talanta. 83 
(2010) 410-424. 
[35] S. Huntscha, H.P. Singer, C.S. McArdell, C.E. Frank, J. Hollender, Multiresidue analysis 
of 88 polar organic micropollutants in ground, surface and wastewater using online mixed-
bed multilayer solid-phase extraction coupled to high performance liquid chromatography-
tandem mass spectrometry, J. Chromatogr. A. 1268 (2012) 74-83. 
 24 
[36] T.A. Ternes, M.Bonerz, N. Herrmann, D. Löffler, E. Keller B.B. Lacida, A.C. Alder, 
Determination of pharmaceuticals, iodinated contrast media and musk fragrances in sludge by 
LC/tandem MS and GC-MS, J. Chromatogr. A. 1067 (2005) 213-223. 
[37] A. Nieto, F. Borrull, E. Pocurull, R.M. Marcé, Pressurized liquid extraction: A useful 
technique to extract pharmaceuticals and personal-care products from sewage sludge, TrAC - 
Trends Anal. Chem. 29 (2010) 752-764. 
[38] A. Jelic, M. Gros, A. Ginebreda, R. Cespedes-Sánchez, F. Ventura, M. Petrovic, D. 
Barcelo, Occurrence, partition and removal of pharmaceuticals in sewage water and sludge 
during wastewater treatment, Water Res. 45 (2011) 1165-1176. 
[39] B.F.D. Silva, A. Jelic, R. López-Serna, A.A. Mozeto, M. Petrovic, D. Barceló, 
Occurrence and distribution of pharmaceuticals in surface water, suspended solids and 
sediments of the Ebro river basin, Spain., Chemosphere. 85 (2011) 1331-1339. 
[40] Y. Chen, Q. Cao, S. Deng, J. Huang, B. Wang, G. Yu, Determination of pharmaceuticals 
from various therapeutic classes in dewatered sludge by pressurized liquid extraction and high 
performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS), Int. J. 
Environ. Anal. Chem. DOI: 10.1080/03067319.2012.717271 (2012) 
[41] O. Zuloaga, P. Navarro, E. Bizkarguenaga, A. Iparraguirre, A. Vallejo, M. Olivares, A. 
Prieto, Overview of extraction, clean-up and detection techniques for the determination of 
organic pollutants in sewage sludge: A review, Anal. Chim. Acta. 736 (2012) 7-29. 
[42] J.-. Zhao, G.-. Ying, L. Wang, J.-. Yang, X.-. Yang, L.-. Yang, X. Li, Determination of 
phenolic endocrine disrupting chemicals and acidic pharmaceuticals in surface water of the 
Pearl Rivers in South China by gas chromatography-negative chemical ionization-mass 
spectrometry, Sci. Total Environ. 407 (2009) 962-974. 
[43] V.G. Samaras, N.S. Thomaidis, A.S. Stasinakis, G. Gatidou, T.D. Lekkasa, 
Determination of selected non-steroidal anti-inflammatory drugs in wastewater by gas 
chromatography-mass spectrometry, Int. J. Environ. Anal. Chem. 90 (2010) 219-229. 
[44] A. Sebok, A. Vasanits-Zsigrai, A. Helenkár, G. Záray, I. Molnár-Perl, Multiresidue 
analysis of pollutants as their trimethyl derivatives, by gas chromatography-mass 
spectrometry, J. Chromatogr. A. 1216 (2009) 2288-2301. 
[45] N. Andrási, A. Helenkár, G. Záray, A. Vasanits, I. Molnár-Perl, Derivatization and 
fragmentation analysis of natural and synthetic steroids, as their trimethylsilyl (oxime) ether 
derivatives by gas chromatography mass spectrometry: Analysis of dissolved steroids in 
wastewater samples, J. Chromatogr. A. 1218 (2011) 1878-1890. 
[46] D. Barceló, M. Petrovic, Challenges and achievements of LC-MS in environmental 
analysis: 25 years on, TrAC - Trends Anal. Chem. 26 (2007) 2-11. 
[47] B. Petrie, E.J. McAdam, M.J. Whelan, J.N. Lester, E. Cartmell, The determination of 
nonylphenol and its precursors in a trickling filter wastewater treatment process, Anal. 
Bioanal. Chem. 405 (2013) 3243-3253. 
 
 25 
[48] S. Marchese, A. Gentili, D. Perret, G. D'Ascenzo, F. Pastori, Quadrupole time-of-flight 
versus triple-quadrupole mass spectrometry for the determination of non-steroidal 
antiinflammatory drugs in surface water by liquid chromatography/tandem mass 
spectrometry, Rapid Comm. Mass Spectr. 17 (2003) 879-886. 
[49] A.C. Chiaia-Hernandez, M. Krauss, J. Hollender, Screening of lake sediments for 
emerging contaminants by liquid chromatography atmospheric pressure photoionization and 
electrospray ionization coupled to high resolution mass spectrometry, Environ. Sci. Technol. 
47 (2013) 976-986. 
[50] D.E. Helbling, J. Hollender, H.-.E. Kohler, H. Singer, K. Fenner, High-throughput 
identification of microbial transformation products of organic micropollutants, Environ. Sci. 
Technol. 44 (2010) 6621-6627. 
[51] Y.-. Duan, C.-. Dai, Y.-. Zhang, Ling-Chen, Selective trace enrichment of acidic 
pharmaceuticals in real water and sediment samples based on solid-phase extraction using 
multi-templates molecularly imprinted polymers, Anal. Chim. Acta. 758 (2013) 93-100. 
[52] K.H. Langford, M.D. Scrimshaw, J.W. Birkett, J.N. Lester, Degradation of 
nonylphenolic surfactants in activated sludge batch tests, Water Res. 39 (2005) 870-876. 
[53] T. Urase, T. Kikuta, Separate estimation of adsorption and degradation of pharmaceutical 
substances and estrogens in the activated sludge process, Water Res. 39 (2005) 1289-1300. 
[54] W.O. Khunjar, N.G. Love, Sorption of carbamazepine, 17α-ethinylestradiol, iopromide 
and trimethoprim to biomass involves interactions with exocellular polymeric substances, 
Chemosphere. 82 (2011) 917-922. 
[55] C.D. Metcalfe, B.G. Koenig, D.T. Bennie, M. Servos, T.A. Ternes, R. Hirsch, 
Occurrence of neutral and acidic drugs in the effluents of canadian sewage treatment plants, 
Environ. Toxicol. Chem. 22 (2003) 2872-2880. 
[56] A. Joss, E. Keller, A.C. Alder, A. Göbel, C.S. McArdell, T. Ternes, H. Siegrist, Removal 
of pharmaceuticals and fragrances in biological wastewater treatment, Water Res. 39 (2005) 
3139-3152. 
[57] M. Bernhard, J. Müller, T.P. Knepper, Biodegradation of persistent polar pollutants in 
wastewater: Comparison of an optimised lab-scale membrane bioreactor and activated sludge 
treatment, Water Res. 40 (2006) 3419-3428. 
[58] N. Nakada, T. Tanishima, H. Shinohara, K. Kiri, H. Takada, Pharmaceutical chemicals 
and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated 
sludge treatment, Water Res. 40 (2006) 3297-3303. 
[59] O.A.H. Jones, N. Voulvoulis, J.N. Lester, The occurrence and removal of selected 
pharmaceutical compounds in a sewage treatment works utilising activated sludge treatment, 
Environ. Pollut. 145 (2007) 738-744. 
 26 
[60] K. Kimura, H. Hara, Y. Watanabe, Elimination of selected acidic pharmaceuticals from 
municipal wastewater by an activated sludge system and membrane bioreactors, Environ Sci. 
Technol. 41 (2007) 3708-3714. 
[61] J. Radjenovic, M. Petrovic, D. Barceló, Analysis of pharmaceuticals in wastewater and 
removal using a membrane bioreactor, Anal. Bioanal. Chem. 387 (2007) 1365-1377. 
[62] S. Zorita, L. Mårtensson, L. Mathiasson, Occurrence and removal of pharmaceuticals in 
a municipal sewage treatment system in the south of Sweden, Sci. Total Environ. 407 (2009) 
2760-2770. 
[63] M. Maurer, W. Pronk, T.A. Larsen, Treatment processes for source-separated urine 
Water Res. 40 (2006) 3151-3166. 
[64] T.L. Zearley, R.S. Summers, Removal of trace organic micropollutants by drinking water 
biological filters, Environ. Sci. Technol. 46 (2012) 9412-9419. 
[65] T.A. Ternes, J. Stüber, N. Herrmann, D. McDowell, A. Ried, M. Kampmann, B. Teiser, 
Ozonation: A tool for removal of pharmaceuticals, contrast media and musk fragrances from 
wastewater?, Water Res. 37 (2003) 1976-1982. 
[66] S.D. Kim, J. Cho, I.S. Kim, B.J. Vanderford, S.A. Snyder, Occurrence and removal of 
pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste 
waters, Water Res. 41 (2007) 1013-1021. 
[67] V. Matamoros, C. Arias, H. Brix, J.M. Bayona, Removal of pharmaceuticals and 
personal care products (PPCPs) from urban wastewater in a pilot vertical flow constructed 
wetland and a sand filter, Environ. Sci. Technol. 41 (2007) 8171-8177. 
[68] N. Nakada, H. Shinohara, A. Murata, K. Kiri, S. Managaki, N. Sato, H. Takada, Removal 
of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting 
chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant, 
Water Res. 41 (2007) 4373-4382. 
[69] S.A. Snyder, S. Adham, A.M. Redding, F.S. Cannon, J. DeCarolis, J. Oppenheimer, E.C. 
Wert, Y. Yoon, Role of membranes and activated carbon in the removal of endocrine 
disruptors and pharmaceuticals, Desalination. 202 (2007) 156-181. 
[70] R. Rosal, A. Rodríguez, J.A. Perdigón-Melón, A. Petre, E. García-Calvo, M.J. Gómez, 
A. Agüera, A.R. Fernández-Alba, Occurrence of emerging pollutants in urban wastewater and 
their removal through biological treatment followed by ozonation, Water Res. 44 (2010) 578-
588. 
[71] H. Schaar, M. Clara, O. Gans, N. Kreuzinger, Micropollutant removal during biological 
wastewater treatment and a subsequent ozonation step, Environ. Poll. 158 (2010) 1399-1404. 
[72] D.P. Grover, J.L. Zhou, P.E. Frickers, J.W. Readman, Improved removal of estrogenic 
and pharmaceutical compounds in sewage effluent by full scale granular activated carbon: 
Impact on receiving river water, J. Hazard. Mater. 185 (2011) 1005-1011. 
 27 
[73] J. Reungoat, B.I. Escher, M. Macova, J. Keller, Biofiltration of wastewater treatment 
plant effluent: Effective removal of pharmaceuticals and personal care products and reduction 
of toxicity, Water Res. 45 (2011) 2751-2762. 
[74] X. Yang, R.C. Flowers, H.S. Weinberg, P.C. Singer, Occurrence and removal of 
pharmaceuticals and personal care products (PPCPs) in an advanced wastewater reclamation 
plant, Water Res. 45 (2011) 5218-5228. 
[75] M.M. Huber, S. Canonica, G.-. Park, U. Von Gunten, Oxidation of pharmaceuticals 
during ozonation and advanced oxidation processes, Environ Sci. Technol. 37 (2003) 1016-
1024. 
[76] L. Gunnarsson, M. Adolfsson-Erici, B. Björlenius, C. Rutgersson, L. Förlin, D.G.J. 
Larsson, Comparison of six different sewage treatment processes-Reduction of estrogenic 
substances and effects on gene expression in exposed male fish, Sci. Total Environ. 407 
(2009) 5235-5242. 
[77] A.O. Ifelebuegu, The fate and behavior of selected endocrine disrupting chemicals in full 
scale wastewater and sludge treatment unit processes Int. J. Environ. Sci. Technol. 8 (2011) 
245-254. 
[78] L. Ho, C. Grasset, D. Hoefel, M.B. Dixon, F.D.L. Leusch, G. Newcombe, C.P. Saint, 
J.D. Brookes, Assessing granular media filtration for the removal of chemical contaminants 
from wastewater, Water Res. 45 (2011) 3461-3472. 
[79] A. Göbel, C.S. McArdell, A. Joss, H. Siegrist, W. Giger, Fate of sulfonamides, 
macrolides, and trimethoprim in different wastewater treatment technologies, Sci. Total 
Environ. 372 (2007) 361-371. 
[80] T. Hashimoto, K. Takahashi, T. Murakami, Characteristics of estrogen decomposition by 
ozonation, Water Sci. Technol. 54 (2006) 87-93. 
[81] M. Wagner, N.P. Ivleva, C. Haisch, R. Niessner, H. Horn, Combined use of confocal 
laser scanning microscopy (CLSM) and Raman microscopy (RM): Investigations on EPS – 
Matrix, Water Res. 43 (2009) 63-76. 
[82] O.A.H. Jones, N. Voulvoulis, J.N. Lester, Human pharmaceuticals in wastewater 
treatment processes, Crit. Rev. Environ. Sci. Technol. 35 (2005) 401-427. 
[83] D.B. Wunder, V.A. Bosscher, R.C. Cok, R.M. Hozalski, Sorption of antibiotics to 
biofilm, Water Res. 45 (2011) 2270-2280. 
[84] M. Hörsing, A. Ledin, R. Grabic, J. Fick, M. Tysklind, J.L.C. Jansen, H.R. Andersen, 
Determination of sorption of seventy-five pharmaceuticals in sewage sludge, Water Res. 45 
(2011) 4470-4482. 
[85] J. Gong, Y. Ran, D. Chen, Y. Yang, E.Y. Zeng, Association of endocrine-disrupting 
chemicals with total organic carbon in riverine water and suspended particulate matter from 
the Pearl River, China., Environ. Toxicol. Chem. 31 (2012) 2456-2464. 
 28 
[86] G. Guibaud, S. Comte, F. Bordas, S. Dupuy, M. Baudu, Comparison of the complexation 
potential of extracellular polymeric substances (EPS), extracted from activated sludges and 
produced by pure bacteria strains, for cadmium, lead and nickel, Chemosphere. 59 (2005) 
629-638. 
[87] J.P. Bagnall, A. Ito, E.J. McAdam, A. Soares, J.N. Lester, E. Cartmell, Resource 
dependent biodegradation of estrogens and the role of ammonia oxidising and heterotrophic 
bacteria, J. Hazard Mater. 239-240 (2012) 56-63. 
[88] L.S. Gaulke, S.E. Strand, T.F. Kalhorn, H.D. Stensel, 17α-ethinylestradiol transformation 
via abiotic nitration in the presence of ammonia oxidizing bacteria, Environ. Sci. Technol. 42 
(2008) 7622-7627. 
[89] J.S. Vader, C.G. Van Ginkel, F.M.G.M. Sperling, J. De Jong, W. De Boer, J.S. De Graaf, 
M. Van Der Most, P.G.W. Stokman, Degradation of ethinyl estradiol by nitrifying activated 
sludge, Chemosphere. 41 (2000) 1239-1243. 
[90] T. Kosjek, E. Heath, S. Pérez, M. Petrović, D. Barceló, Metabolism studies of diclofenac 
and clofibric acid in activated sludge bioreactors using liquid chromatography with 
quadrupole - time-of-flight mass spectrometry, J. Hydrology. 372 (2009) 109-117. 
[91] S. Carbonaro, M.N. Sugihara, T.J. Strathmann, Continuous-flow photocatalytic treatment 
of pharmaceutical micropollutants: Activity, inhibition, and deactivation of TiO2 
photocatalysts in wastewater effluent, Applied Catalysis B: Environmental. 129 (2013) 1-12. 
[92] J.L. Chen, S. Ravindran, S. Swift, L.J. Wright, N. Singhal, Catalytic oxidative 
degradation of 17α-ethinylestradiol by FeIII-TAML/H202: Estrogenicities of the products of 
partial, and extensive oxidation, Water Res. 46 (2012) 6309-6318. 
[93] M.M. Huber, T.A. Ternes, U. Von Gunten, Removal of estrogenic activity and formation 
of oxidation products during ozonation of 17α-ethinylestradiol, Environ. Sci. Technol. 38 
(2004) 5177-5186. 
[94] J. Hoigne, H. Bader, Rate constants of reactions of ozone with organic and inorganic 
compounds in water. I. Non-dissociating organic compounds, Water Res. 17 (1983) 173-183. 
[95] S.A. Snyder, P. Westerhoff, Y. Yoon, D.L. Sedlak, Pharmaceuticals, personal care 
products, and endocrine disruptors in water: Implications for the water industry, Environ. 
Eng. Sci. 20 (2003) 449-469. 
[96] A.D. Coelho, C. Sans, A. Agüera, M.J. Gómez, S. Esplugas, M. Dezotti, Effects of ozone 
pre-treatment on diclofenac: Intermediates, biodegradability and toxicity assessment, Sci. 
Total Environ. 407 (2009) 3572-3578. 
[97] C.-. Chiu, K. Hristovski, S. Huling, P. Westerhoff, In-situ regeneration of saturated 
granular activated carbon by an iron oxide nanocatalyst, Water Res. 47 (2013) 1596-1603. 
[98] Environment Agency, Endocrine Disrupting Substances in the Environment: The 
Environment Agency's Strategy, Environment Agency, HMSO, London, UK. 2000. 
 29 
[99] D.R. Baker, B. Kasprzyk-Hordern, Critical evaluation of methodology commonly used in 
sample collection, storage and preparation for the analysis of pharmaceuticals and illicit drugs 
in surface water and wastewater by solid phase extraction and liquid chromatography-mass 
spectrometry, J. Chromatogr. A. 1218 (2011) 8036-8059. 
[100] J. Shen, X. Jin Yang, A.I. Schäfer, Quantification of hormone-humic acid interactions 
in nanofiltration, Environ. Sci. Technol. 46 (2012) 10597-10604. 
 
 
 
